AgTech Greenhouse - Agriculture Precision Agriculture

CO2 GRO Inc. announces a Commercial Feasibility with Plant Advanced Technologies PAT in France in conjunction with marketing partner Rika Biotech

Toronto based CO2 GRO Inc. (“GROW”) (TSXV: GROW, OTCQB: BLONF, Frankfurt: 4021) is pleased to announce its first commercial feasibility in the EU with France based Plant Advanced Technologies PAT (“PAT”) (EURONEXT GROWTH Paris ISIN: FR0010785790 ALPAT). It is also the first partnership with its UK based Marketing Partner Rika Biotech (“Rika”) that is exclusively representing CO2 Delivery Solutions™ in the UK, the Netherlands and Belgium greenhouse markets.

The commercial feasibility is on medicinal plants and is the first on such plants other than Cannabis and hemp. PAT contacted GROW directly concerning CO2 Delivery Solutions™. While Rika is exclusive to certain EU countries, their experience in many other EU countries is valuable to help execute successful projects on a non-exclusive basis.

PAT extracts medicinal, nutraceuticals, cosmetical and plant-protection compounds from various wild plant biomass and roots. Their 7.5 acres Nancy, France based greenhouse (30,000 m²) does not employ CO2 gassing. The commercial feasibility will run for 6 months in a small section of their greenhouse.

Jean-Paul Fèvre, CEO of PAT commented, “We are excited to test the CO2 Delivery Solutions™ technology. I came across CO2 GRO online a few months back. Since our greenhouse does not currently use CO2 gassing, we believe our yields are lower than they could be. We grow a variety of medicinal plants for extracting compounds primarily from the roots. Previous data has shown enhanced biomass with added CO2 and we hope to achieve the same results on our plants.”

Gregory Krupnikovs, Director at Rika Biotech commented, “We are delighted to support GROW and PAT execute the first commercial feasibility in Europe. This is a key milestone as Rika develops the market for GROW’s exciting technology in our exclusive markets and other non-exclusive countries in Europe. Applying this technology to the fast-growing market for greenhouse produced medicinal plants shows just how flexible the system is; bringing the benefits of CO2 enrichment with vastly reduced CO2 usage to any type of covered crop.”

Aaron Archibald, VP Sales & Strategic Alliances commented, “We are very excited to be working with PAT given their unique focus on growing very high value medicinal plant varieties. Success could lead to working with growers of other very high value plants such as biopharming grown for human drugs and vaccines. We continue to see significant interest from greenhouse growers in many diverse market segments. Our global recognition continues to gain increasing momentum thanks to ongoing marketing initiatives, our online presence, sales and marketing efforts and the work of our valued regional partners like Rika Biotech who enable us to manage these international clients successfully.”

About Plant Advanced Technologies PAT –

Plant Advanced Technologies PAT is specialized in the identification, optimization and production of rare new active plant compounds for cosmetics, pharmaceuticals, and nutraceutical and agrochemical markets. Since its creation, the company has developed unique worldwide patented technologies for fast discovery of active molecules and their industrial production while preserving plant biodiversity (Target Binding® and PAT Plant Milking®).

About CO2 GRO Inc.

GROW’s target markets are focused on the 50 billion square feet of global greenhouse and covered cultivation space (USDA). Atmospheric enrichment of CO2 by gassing has been practiced in indoor and expensive sealed greenhouses for decades resulting in enhance crop yields of up to 30%. However, 85% of the world’s greenhouses are unsealed and have open-venting designs for heat ventilation which makes CO2 gassing uneconomical and impractical since the CO2 gas easily escapes. GROW’s CO2 Delivery SolutionsTM naturally and safely dissolves CO2 gas into water creating an aqueous CO2 solution which is then misted directly on plant leaves. GROW has demonstrated its technology to be as effective as CO2 gassing by improving crop yields up to 30%, while using a fraction of the CO2 gas. The CO2 solution’s micro droplets create an aqueous film around the entire leaf surface, isolating the leaf from the atmosphere. This creates a diffusion gradient favoring CO2 transport into the leaf and other gases out of the leaf. Increased carbon availability enhances photosynthesis resulting in faster and larger plant growth. CO2 Delivery SolutionsTM has been demonstrated on crops including Cannabis, hemp, lettuce, kale, microgreens, peppers and flowers. In addition, aqueous CO2 misting offers pathogen Perimeter ProtectionTM for plants by slowing the spread of micro pathogens such as E. coli and powdery mildew. Greenhouse growers everywhere can now supplement CO2 to their crops using CO2 Delivery SolutionsTM, increasing plant yields and profits.

CO2 Delivery SolutionsTM VCO2 system installation

To contact Jason Field, please call +27 82 560 3618 or e-mail at Visit for more information on CO2 Delivery SolutionsTM.

Forward-Looking Statements 

This press release contains statements which constitute “forwardlooking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities. Forward‐ looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions and include information regarding: statements regarding the future direction of the Company; the ability of the Company to successfully achieve its business and financial objectives; plans for expansion and the ability of the Company to obtain, develop and foster its business relationships; and expectations for other economic, business, and/or competitive factors. Investors are cautioned that forwardlooking information is not based on historical facts but instead reflect the Company’s management’s expectations, estimates or projections concerning the business of the Company’s future results or events based on the opinions, assumptions and estimates that management considered reasonable at the date the statements are made. Such assumptions include but are not limited to: general business and economic conditions; the Company’s ability to successfully execute its plans and intentions; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and technology offered by the Company’s competitors; and that good relationships with business partners will be maintained. Although the Company believes that the expectations reflected in such forwardlooking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forwardlooking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; in particular, in the ability of the Company to raise debt and equity capital in the amounts and at the costs that it expects; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; the biotechnology industry and the greenhouse growers market are highly competitive, and technical advances in the industry will impact the success of the Company, and other risks described in the Company’s filings that are available at Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forwardlooking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forwardlooking information except as otherwise required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information, please visit or contact Michael O’Connor, Investor Relations Manager at 604-317-6197 or